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and infectivity
Ludovico Cantuti-Castelvetri1,2*, Ravi Ojha3*, Liliana D. Pedro1,2*, Minou Djannatian1,2*, Jonas Franz4,5,6*,
Suvi Kuivanen7*, Franziska van der Meer4, Katri Kallio3, Tuğberk Kaya1,2,8, Maria Anastasina3,9,
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The causative agent of coronavirus disease 2019 (COVID-19) is the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). For many viruses, tissue tropism is determined by the availability of virus
receptors and entry cofactors on the surface of host cells. In this study, we found that neuropilin-1
(NRP1), known to bind furin-cleaved substrates, significantly potentiates SARS-CoV-2 infectivity, an
effect blocked by a monoclonal blocking antibody against NRP1. A SARS-CoV-2 mutant with an altered
furin cleavage site did not depend on NRP1 for infectivity. Pathological analysis of olfactory epithelium
obtained from human COVID-19 autopsies revealed that SARS-CoV-2 infected NRP1-positive cells
facing the nasal cavity. Our data provide insight into SARS-CoV-2 cell infectivity and define a potential
target for antiviral intervention.
A
n outbreak of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2)
infections has caused a pandemic asso-
ciated with a severe acute pulmonary
disease named COVID-19 (coronavirus
disease 2019) (1). A related coronavirus, SARS-
CoV, led to a much smaller outbreak in 2003,
possibly due to infection occurring predomi-
nantly in the lower respiratory system, where-
as SARS-CoV-2 spreads rapidly through active
pharyngeal viral shedding (2). Despite these
differences, uptake of both viruses is mediated
by the same cellular receptor: angiotensin-
converting enzyme 2 (ACE2) (3–5). One hy-
pothesis to explain the enhanced spreading
of SARS-CoV-2 is the presence of a polybasic
furin-type cleavage site, RRAR^S, at the S1-S2
junction in the SARS-CoV-2 spike (S) protein
that is absent in SARS-CoV (6). Similar sequences
are found in the S proteins of many other path-
ogenic human viruses, including Ebola, HIV-1,
and highly virulent strains of avian influenza
(6, 7). The presence of the polybasic cleavage
site in SARS-CoV-2 results in enhanced path-
ogenicity by priming the fusion activity (8) and
could potentially create additional cell surface
receptor binding sites. Proteolytic cleavage
of RRAR^S by furin exposes a conserved C-
terminal motif, RXXROH [where R is arginine
and X is any amino acid; R can be substituted
by lysine (K)], in the S protein. Such C-terminal
sequences that conformto theC-end rule (CendR)
are known to bind to and activate neuropilin
(NRP1 and NRP2) receptors at the cell surface
(9). Recent cryo–electron microscopy struc-
tures of the SARS-CoV-2 S protein demon-
strated that the S1-S2 junction is part of a
solvent-exposed loop and is therefore acces-
sible for receptor interactions (10, 11).
To determine whether SARS-CoV-2 can use
NRP1 for virus entry and infectivity, we gen-
erated lentiviral particles pseudotyped with
the SARS-CoV-2 S protein. Pseudoviruses are
well suited for virus entry assays, as they allow
viral entry to be distinguished from other vi-
rus life-cycle steps. Human embryonic kidney
293 T (HEK-293T) cells, which have almost no
detectableACE2 andNRP1 transcripts (fig. S1),
were transfected with plasmids that encode
the two established host factors (4), human
ACE2 and the transmembrane protease serine
2 (TMPRSS2), orNRP1.When expressed alone,
ACE2 rendered cells susceptible to infec-
tion (Fig. 1A). AlthoughNRP1 did not promote
infection in HEK-293T cells, its coexpres-
sion with ACE2 and TMPRSS2 markedly
enhanced infection (Fig. 1, A and B). NRP1 ex-
pression increased infection in Caco-2 cells,
which endogenously express ACE2 (12) (Fig. 1C
and fig. S1D), showing thatNRP1 can potentiate
infection in the presence of other host factors.
To test the specificity of NRP1-dependent virus
entry, we developed monoclonal antibodies
(mAbs) that were designed to functionally block
the extracellular b1b2 domain of NRP1, which
is known tomediate binding to CendR peptides
(13). The mAb3 was observed to bind to the re-
combinant b1b2 domain of wild-type (WT)
NRP1 but not to the triple-mutant b1b2 do-
main (S346A, E348A, and T349A in the CendR
binding pocket) (fig. S2A). The potency of the
mAbs in preventing cellular binding and in-
ternalization of NRP ligands was tested using
80-nm silver nanoparticles (AgNP) coated with
the prototypic NRP1-binding CendR peptide
RPARPAROH (9) (fig. S2B). mAb3 efficiently
blocked AgNP-CendR binding (fig. S2C) and
internalization (fig. S2, D and E), whereas an-
othermonoclonal antibody,mAb2, hadno effect
andwasused as a control in further experiments.
Treatment ofHEK-293TwithmAb3 significantly
reduced infection by SARS-CoV-2 pseudoviruses
in cells expressing ACE2, TMPRSS2, and NRP1
(Fig. 1D), but not in cells expressing ACE2 and
TMPRSS2 only (fig. S2F). When SARS-CoV-2
pseudovirus was preincubated with recom-
binant, soluble extracellular b1b2 domain of
NRP1, the wild type significantly reduced in-
fection compared with the triple mutant (Fig.
1E and fig. S2G).
Next, we explored the role of NRP1 using
SARS-CoV-2 isolated from COVID-19 patients
from theHelsinki University Hospital. We used
WT SARS-CoV-2 and a cleavage-impaired SARS-
CoV-2 mutant that was isolated from Vero-E6
cells, which rapidly accumulate mutations at
the furin cleavage site of the S protein dur-
ing passaging (Fig. 2, A and B) (14). First, we
confirmed that furin cleaved the WT, but not
themutant, SARS-CoV-2 S protein by analyz-
ing S protein processing in Chinese hamster
ovary cells with functional (parental) or deficient
(FD11) furin enzyme (fig. S3) (15). Next, we
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validated that exogenous ACE2 expression ren-
dered HEK-293T cells susceptible to infection
with SARS-CoV-2 (Fig. 2, C and D). NRP1 ex-
pression alone caused lower levels of infection,
which were detectable only with increasing
virus titer (Fig. 2, C and D). We then compared
the ability of WT and mutant SARS-CoV-2 to
infect HEK-293T that stably express ACE2;
ACE2 andTMPRSS2; or ACE2, TMPRSS2, and
NRP1. Infection of these cell lines by the WT,
but not the mutant, virus increased in the pres-
ence of NRP1, providing further evidence that
NRP1 requires a furin-cleaved substrate for its
effects (Fig. 2, E and F). We studied the effect of
the NRP1-blocking antibody, mAb3, on infec-
tion of Caco-2 cells by WT and mutant SARS-
CoV-2 and found that preincubation with
NRP1-blocking antibody reduced WT virus
infection by ~40%, whereas the control mAb2
had no effect (Fig. 2, G and H). NRP1-blocking
antibody had no effect on the infection by the
mutated virus (Fig. 2, G and H).
Cleavage of SARS-CoV-2 S protein at the
S1-S2 site generates the C-terminal end se-
quence TQTNSPRRAROH. To determinewheth-
er this specific sequence can function as a
substrate for NRP1, we used AgNPs coated
with TQTNSPRRAROH peptide or different
control peptides, including one with a ter-
minal amide group (TQTNSPRRARNH2), which
reduces NRP1 binding (9) (Fig. 3A). We found
that AgNP-TQTNSPRRAROH, but not control
AgNPs, were efficiently taken up byHEK-293T
cells expressingNRP1 (Fig. 3, B andC). Next, we
determined whether AgNP-TQTNSPRRAROH
particles were also internalized into cells in vivo.
We chose to study nanoparticle entry in the
mouse olfactory epithelium, owing to the known
expression of NRP1 in the olfactory system (16),
including olfactory neuronal cells of the epithe-
lium (fig. S4). AgNPs-TQTNSPRRAROHand con-
trol AgNP-TQTNSPRRARNH2were administered
into the nose of anesthetized adult mice. Six
hours after administration, we observed a sig-
nificantly largeruptakeofAgNP-TQTNSPRRAROH
than of AgNP-TQTNSPRRARNH2 into the ol-
factory epithelium (Fig. 3, D and E) and, un-
expectedly, into neurons and blood vessels of
the cortex (Fig. 3, F and G). Similar results
were obtained for AgNPs coated with the pro-
totypic NRP1-binding CendR peptide RPAR-
PAROH (fig. S5).
Having obtained evidence for a role of NRP1
in cell entry of SARS-CoV-2, we examined whether
NRP1 expression correlated with the detection
of virus RNA in single-cell transcriptomes. For
these analyses, we used published single-cell
RNA sequencing (scRNA-seq) datasets of cul-
tured experimentally infected human bron-
chial epithelial cells and cells isolated from
bronchoalveolar lavage fluid (BALF) of severely
affected COVID-19 patients (17). Among the
proposed entry and amplification factors, NRP1,
FURIN, and TMPRSS11Awere enriched in SARS-
CoV-2–infected cells compared with noninfected
cells (fig. S6). We also detected increased ex-
pression of these proteins after infection (fig.
S6). In addition, RNA expression of NRP1 and
its homolog NRP2 was elevated in SARS-CoV-
2–positive cells compared with adjacent cells
in the BALF of severely affected COVID-19 pa-
tients (fig. S7).
Because the availability of virus receptors
and entry cofactors on the surface of host cells
determines infectivity, we compared the ex-
pression patterns of ACE2 and NRP1 in pub-
lished scRNA-seq datasets of human lung tissue
(18) and human olfactory epithelium (19).
Whereas ACE2 was detected at very low lev-
els, bothNRP1 andNRP2were abundantly ex-
pressed in almost all pulmonary and olfactory























































































































































Fig. 1. NRP1 facilitates the cellular entry of SARS-CoV-2 pseudotyped particles.
(A) Representative images and quantification of SARS-CoV-2 S protein (SARS-2)
(blue bars) and vesicular stomatitis virus glycoprotein (VSV-G) pseudotype (gray
bars) infectivity in HEK-293T cells transiently expressing control (ctrl) vector,
ACE2, NRP1, or TMPRSS2 (TSS2). Data are normalized to the respective
infectivity of SARS-2 and VSV-G pseudotype in ACE2-expressing cells. Two-way
analysis of variance (ANOVA) was carried out with Tukey’s correction for multiple
comparisons. (B) HEK-293T cells transiently expressing ACE2 and TMPRSS2
or NRP1, ACE2, and TMPRSS2 were inoculated with SARS-2 pseudotype. Data are
normalized to SARS-2 infectivity in cells expressing ACE2 and TMPRSS2. One-
way ANOVA was performed with Tukey’s correction for multiple comparisons.
(C) SARS-2 pseudotype infectivity in Caco-2 cells expressing NRP1 or control
vector. Data are normalized to the respective infectivity of SARS-2 and VSV-G
pseudotype in control cells. Two-way ANOVA was carried out with Sidak’s
correction for multiple comparisons. (D and E) HEK-293T cells transiently
expressing NRP1, ACE2, and TMPRSS2 were inoculated with SARS-2 pseudotype
in the presence of mAb3 antibody against NRP1 [(D), mAb3] or control mAb2
[(D), ctrl Ab] and in the presence of soluble NRP1 wild-type b1b2 domain
[(E), wt b1b2] or NRP1 mutant b1b2 domain [(E), mut b1b2]. Data in (E) are
normalized to untreated cells expressing NRP1, ACE2, and TMPRSS2. Two-tailed
unpaired Student’s t test was performed. All data are represented as means ± SDs
from three independent experiments [(A) to (C)] or three biological replicates
[(D) and (E)]. *P < 0.05, **P < 0.01, ****P < 0.0001. All images show GFP-positive,
infected cells (magenta) and Hoechst stain (cyan). Scale bars, 100 mm.
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cells, with the highest levels of expression in
endothelial cells (figs. S8 and S9). We con-
firmed these results by examining NRP1 im-
munoreactivity in human autopsy tissue and
detected NRP1 in the epithelial surface layer
of the human respiratory and olfactory epi-
thelium (fig. S10A). ACE2 was hardly de-
tectable in these tissues (fig. S10B). Within
the olfactory epithelium, NRP1 was also ob-
served in cells positive for oligodendrocyte
transcription factor 2 (OLIG2), which is mostly
expressed by olfactory neuronal progenitors
(fig. S10C).
In light of the widely reported disturbance
of olfaction in a large fraction of COVID-19
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Fig. 2. A blocking antibody against
the b1b2 domain of NRP1 reduces
infection by wild-type SARS-CoV-2
(SARS-2-wt) but not a mutant with a
deletion at the furin-cleavage site
(SARS-2-mut). (A) Sequence analysis of
viruses isolated at different passages
(P) from different cell types. The first
sequence is the reference from the
Wuhan isolate (NC_045512.2). The
sequence abundance in each virus pop-
ulation is indicated as a percentage.
ND, not determined. §, SARS-2-wt; §§,
SARS-2-mut. A, Ala; S, Ser; Y, Tyr; Q,
Gln; T, Thr; N, Asn; P, Pro; R, Arg; V, Val.
(B) A deletion adjacent to the furin-
cleavage site abrogates the enzymatic
cleavage of the S protein. Immunoblot
analysis was carried out on cell lysates
from Vero-E6 cells infected for 16 hours
with two viral populations (§ and §§).
Numbers indicate protein size (in kilo-
daltons). (C and D) Representative
images and quantification of SARS-2-wt
infectivity in HEK-293T cells stably
expressing ACE2 (blue bars) or NRP1
(orange bars) compared with nontrans-
fected cells (gray bars). Different virus
titers were used. Data are normalized to
the infectivity in ACE2-expressing cells
at multiplicity of infection (MOI) = 5.
Two-way ANOVA was done with Tukey’s
correction for multiple comparisons.
(E and F) Representative images (E) and
quantification (F) of HEK-293T cells
stably expressing the indicated combi-
nations of ACE2, TMPRSS2 (TSS2), and
NRP1 after inoculation with SARS-2-wt
(wt; blue bars) or SARS-2-mut (mut;
gray bars). Data are normalized to the
respective infectivity in ACE2-expressing
cells. Two-way ANOVA was performed
with Tukey’s correction for multiple
comparisons. (G and H) Caco-2 cell
infection in the presence of control
mAb2 (ctrl. Ab) or mAb3 blocking anti-
bodies against NRP1 after SARS-2-wt
(wt; blue bars) or SARS-2-mut (mut;
gray bars) inoculation. Data are normal-
ized to the respective vehicle control
(phosphate-buffered saline) sample.
Two-way ANOVA was performed with
Tukey’s correction for multiple compar-
isons. Data are means ± SDs from three
independent experiments. *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001. Magenta, SARS-2-wt– and SARS-2-mut–infected cells; Hoechst stain, cyan. Scale bars, 50 mm.
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patients (20, 21) and the enrichment of NRPs
in the olfactory epithelium,we analyzed a series
of autopsies from six COVID-19 patients and
eight noninfected control patients to determine
whether SARS-CoV-2 could infect NRP1-positive
cells (Fig. 4 and table S1). Using antibodies
against the S protein, we detected infection of
the olfactory epithelium in five of six COVID-19
patients. The infected olfactory epithelial cells
showed high expression of NRP1 (Fig. 4, A
and B). Additional costaining indicated in-
fection of cells positive for OLIG2 (Fig. 4B
and fig. S11).
There is limited knowledge about the virus–
host interactions that determine cellular entry
of SARS-CoV-2. Viruses display considerable
redundancy and flexibility because they can
exploit weak multivalent interactions to en-
hance affinity. To date, studies of SARS-CoV-2
entry have focused almost entirely on ACE2,
which is expressed at very low protein levels
in respiratory and olfactory epithelial cells
(22). This raises the possibility that cofactors
are required to facilitate virus–host cell in-
teractions in cells with low ACE2 expression.
NRP1 could represent such an ACE2 poten-
tiating factor by promoting the interaction
of the virus with ACE2. The reason a number
of viruses (23–26) use NRPs as entry factors
may be their high expression on epithelia facing
the external environment and their function in




ing of S protein (brown)
and NRP1 (purple) in the
apical olfactory epithe-
lium (OE) in a nonin-
fected control (left) and
in the apical OE (middle)
and adjacent mucosa
(right) in a COVID-19
patient. LP, lamina
propria; HB, horizontal
basal cells. (B) Costain-
ing of NRP1 (magenta) or
OLIG-2 (magenta) with
S protein (yellow) in
OE cells. Nuclei are














































































































Fig. 3. NRP mediates entry of nanoparticles coated with SARS-CoV-2
(SARS-2) S–derived CendR peptides into cultured cells, olfactory epithe-
lium, and the central nervous system of mice. (A) Peptide sequences used
for AgNP coating. The peptides mimic SARS-2 S protein after furin cleavage
(post) and as controls; S protein before cleavage (pre), in which the terminal
amino acid is replaced by alanine (Ala); or with an amide terminus (post
amide). X, any amino acid. The arrow indicates the cleavage site. (B and C)
Representative images and quantification of the internalization of peptide-coated
AgNPs in HEK-293T cells expressing NRP1. Merged images show AgNP-positive
cells (magenta) and Hoechst stain (cyan). One-way ANOVA was carried out with
Tukey’s correction for multiple comparisons. (D to G) Representative images and
quantification of the main olfactory epithelium [(D) and (E), respectively] and
cortex [(F) and (G), respectively] 6 hours after intranasal administration of
AgNPs coated with SARS2-post and SARS2-post amide peptides. n = 4 replicates
for (C); n = 5 (E) and n = 4 (G) mice per condition. Data are means ± SDs.
Two-tailed unpaired Student’s t test; *P < 0.05, ***P < 0.001. Magenta,
AgNPs; cyan, Hoechst stain; green, NeuN (neuronal marker); yellow, AQP4.
Scale bars, 100 mm (B), 20 mm [(D) and (F)].
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enabling cell, vascular, and tissue penetration
(9, 13).
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SARS-CoV-2 contains a cleavage site for the protease furin that is absent from SARS-CoV (see the Perspective by 
however, their tissue tropism differs, raising the possibility that additional host factors are involved. The spike protein of
coronavirus 2 (SARS-CoV-2) and the earlier SARS-CoV use angiotensin-converting enzyme 2 (ACE2) as a receptor; 
Virus-host interactions determine cellular entry and spreading in tissues. Severe acute respiratory syndrome
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